Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 20/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 20/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 20/20 | 0.70 |
| ▸ | PDE3B | Q13370 | 20/20 | 0.70 |
| ▸ | PDE3A | Q14432 | 20/20 | 0.70 |
| ▸ | PDE5A | O76074 | 19/20 | 0.70 |
| ▸ | PDE1A | P54750 | 14/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 14/20 | 0.50 |
| ▸ | PDE1C | Q14123 | 14/20 | 0.50 |
| ▸ | PDE2A | O00408 | 2/20 | 0.46 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.46 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623702 | 1.00 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7285109 | 0.97 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL2473235 | 0.91 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL15085278 | 0.90 | PDE5A (0.57) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7289581 | 0.86 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL15085332 | 0.86 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL12013957 | 0.83 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7287261 | 0.82 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7285598 | 0.79 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7279127 | 0.77 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 493 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2828242-B1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | ALMIRALL SA (ES) | 2017-10-04 | — | — | EP | claimed |
| US-9346759-B2 | Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor | ALMIRALL, S.A. (ES) | 2016-05-24 | — | — | US | claimed |
| US-20150057256-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ALMIRALL S.A. (ES) | 2015-02-26 | — | — | US | claimed |
| EP-2641900-A1 | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. | Almirall, S.A. (ES) | 2013-09-25 | — | — | EP | claimed |
| EP-2121615-B1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-03-28 | — | — | EP | claimed |
| US-20110195943-A9 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2011-08-11 | — | — | US | claimed |
| US-20100093681-A1 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL, S.A. (ES) | 2010-04-15 | — | — | US | claimed |
| US-7659273-B2 | adminstering phosphodiesterase-4 inhibitor selected from 2,3-bis(hydroxymethyl)-6,7-diethoxy-1-[1-(2-methoxyethyl)-2-oxo-4-pyridyl]naphthalene or 2,3-bis(hydroxymethyl) -6,7-diethoxy-1-[2-(4-(3-pyridyl)-1(2H)-phthaladinon-2-yl)-4-pyridyl]naphthalene | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-09 | — | — | US | claimed |
| US-20080031958-A1 | adminstering phosphodiesterase-4 inhibitor selected from 2,3-bis(hydroxymethyl)-6,7-diethoxy-1-[1-(2-methoxyethyl)-2-oxo-4-pyridyl]naphthalene or 2,3-bis(hydroxymethyl) -6,7-diethoxy-1-[2-(4-(3-pyridyl)-1(2H)-phthaladinon-2-yl)-4-pyridyl]naphthalene | TANABE SEIYAKU CO., LTD. | 2008-02-07 | — | — | US | claimed |
| US-20070155652-A1 | Composition for regenerative treatment of cartilage disease | TANABE SEIYAKU CO., LTD. | 2007-07-05 | — | — | US | claimed |
| US-20040180900-A1 | Therapeutic composition for repairing chondropathy | TANABE SEIYAKU CO., LTD. (JP) | 2004-09-16 | — | — | US | claimed |
| US-20040146561-A1 | Compositions for promoting healing of bone fracture | TANABE SEIYAKU CO., LTD. (JP) | 2004-07-29 | — | — | US | claimed |
| EP-1389468-A1 | COMPOSITIONS FOR PROMOTING HEALING OF BONE FRACTURE | TANABE SEIYAKU CO., LTD. (JP) | 2004-02-18 | — | — | EP | claimed |
| EP-1389467-A1 | THERAPEUTIC COMPOSITIONS FOR REPAIRING CHONDROPATHY | TANABE SEIYAKU CO., LTD. (JP) | 2004-02-18 | — | — | EP | claimed |
| EP-0557016-B1 | Naphthalene derivatives, processes for preparing the same, and synthetic intermediates therefor | TANABE SEIYAKU CO (JP) | 1996-06-19 | — | — | EP | claimed |
| US-5342941-A | Bronchodilating agents | TANABE SEIYAKU CO., LTD. (JP) | 1994-08-30 | — | — | US | claimed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-5342941-A | Bronchodilating agents | TANABE SEIYAKU CO., LTD. (JP) | 1994-08-30 | — | — | US | disclosed |
| EP-0557016-A1 | Naphthalene derivatives, processes for preparing the same, and synthetic intermediates therefor | TANABE SEIYAKU CO., LTD. (JP) | 1993-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115561-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | CFTR, SCNN1B, SCNN1G | PDE4A 455/4885PDE4B 330/4885PDE4C 534/4885 |
| US-20080031958-A1 | adminstering phosphodiesterase-4 inhibitor selected from 2,3-bis(hydroxymethyl)-6,7-diethoxy-1-[1-(2-methoxyethyl)-2-oxo-4-pyridyl]naphthalene or 2,3-bis(hydroxymethyl) -6,7-diethoxy-1-[2-(4-(3-pyridyl)-1(2H)-phthaladinon-2-yl)-4-pyridyl]naphthalene | PDE4A, PDE7A, PDE4B | PDE4A 1/4885PDE4B 3/4885PDE4C 7/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | PDE4A 357/4885PDE4B 399/4885PDE4C 506/4885 |
| US-20040180900-A1 | Therapeutic composition for repairing chondropathy | PDE4B, PDE4A, PDE4C | PDE4A 2/4885PDE4B 1/4885PDE4C 3/4885 |
| US-20150057256-A1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2--1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYTLATE AS AGONIST OF THE BETA2 ADRENERGIC RECEPTOR | ADRA2C, ADRB2, ADRA2A | PDE4A 367/4885PDE4B 274/4885PDE4C 462/4885 |
| US-20100093681-A1 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ADRA2C, ADRB2, ADRA2A | PDE4A 261/4885PDE4B 237/4885PDE4C 361/4885 |
| US-20040146561-A1 | Compositions for promoting healing of bone fracture | PDE4B, PDE4A, PDE4D | PDE4A 2/4885PDE4B 1/4885PDE4C 4/4885 |
| US-20070155652-A1 | Composition for regenerative treatment of cartilage disease | PDE4B, PDE4A, PDE4C | PDE4A 2/4885PDE4B 1/4885PDE4C 3/4885 |
| US-20110195943-A9 | NAPADISYLATE SALT OF 5-(2--1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ADRA2C, ADRB2, ADRA2A | PDE4A 261/4885PDE4B 237/4885PDE4C 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.